# CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
Canonical URL: https://biopharmsignal.com/news/CTMX/cytomx-announces-expansion-of-strategic-research-collaboration-with-regeneron-in-the-field-of-conditional-bispecific-therapeutics-for-the-treatment-of-cancer
Ticker: CTMX
Company: CytomX Therapeutics, Inc.
Source: CytomX Therapeutics, Inc.
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.cytomx.com
## Summary

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY ® and Regeneron's Veloci-Bi ® platforms - - CytomX to receive $37 million target selection payment for two additional programs selected - - Regeneron secures option

## Article Body
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY ® and Regeneron's Veloci-Bi ® platforms - - CytomX to receive $37 million target selection payment for two additional programs selected - - Regeneron secures option
## Recent Company News
- 2026-06-25 13:46 EST — [CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer](https://biopharmsignal.com/news/CTMX/cytomx-announces-expansion-of-strategic-research-collaboration-with-regeneron-in-the-field-of-conditional-bispecific-therapeutics-for-the-treatment-of-cancer) — Source: CytomX Therapeutics, Inc.
- 2026-06-25 13:46 EST — [CytomX Therapeutics to Present at Upcoming June Investor Conferences](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-june-investor-conferences) — Source: CytomX Therapeutics, Inc.
- 2026-06-25 13:46 EST — [CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-appoints-mamata-gokhale-ph-d-rac-as-senior-vice-president-of-regulatory-affairs) — Source: CytomX Therapeutics, Inc.
- 2026-06-25 13:46 EST — [CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-announces-q1-2026-financial-results-and-provides-business-update) — Source: CytomX Therapeutics, Inc.
- 2026-06-25 13:46 EST — [CytomX Therapeutics to Present at the Jefferies London Healthcare Conference](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-present-at-the-jefferies-london-healthcare-conference) — Source: CytomX Therapeutics, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)